Compare HURA & TCGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | HURA | TCGX |
|---|---|---|
| Founded | 2009 | 2026 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.5M | 159.4M |
| IPO Year | 2010 | 2026 |
| Metric | HURA | TCGX |
|---|---|---|
| Price | $1.76 | $12.88 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $8.04 | N/A |
| AVG Volume (30 Days) | ★ 211.8K | 9.0K |
| Earning Date | 11-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.93 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $11.62 |
| 52 Week High | $3.43 | $18.91 |
| Indicator | HURA | TCGX |
|---|---|---|
| Relative Strength Index (RSI) | 34.17 | 46.95 |
| Support Level | $1.27 | $12.42 |
| Resistance Level | $1.83 | $15.25 |
| Average True Range (ATR) | 0.10 | 0.97 |
| MACD | -0.02 | -0.12 |
| Stochastic Oscillator | 14.93 | 21.34 |
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
TCGX Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities.